Literature DB >> 24732387

The potentially protective effect of donepezil in Alzheimer's disease.

Akiko Ishiwata1, Sunao Mizumura, Masahiro Mishina, Mineo Yamazaki, Yasuo Katayama.   

Abstract

BACKGROUND/AIMS: Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease (AD). In this study, we used a voxel-based specific regional analysis system for AD (VSRAD) to analyze the hippocampal volume and to assess the pharmacologic effects of donepezil as a disease modifier.
METHODS: A total of 185 AD patients underwent MRI, 120 (43 men and 77 women, 77.8 ± 7.1 years) without and 65 (29 men and 36 women, 78.4 ± 6.0 years) with donepezil treatment. VSRAD was compared in both groups and against a database of 80 normal subjects. The Z-score was used to assess the degree of hippocampal atrophy.
RESULTS: No significant difference between the groups was found for age, sex, or Z-scores, but a significant difference was found for mean Mini-Mental State Examination (MMSE) scores (p = 0.02, Student's t test). Single regression analysis showed no significant association between Z-scores and MMSE scores in the treated group (p = 0.494), but a significant association in the untreated group (p = 0.001) was observed. This implies that the MMSE score becomes lower when the Z-score is higher in the untreated group, whereas there is no significant trend in the treated group.
CONCLUSION: Donepezil affects the relationship between hippocampal volume and cognitive function and may therefore have a pharmacologic effect as a disease modifier.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24732387     DOI: 10.1159/000358510

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  3 in total

1.  Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition?

Authors:  Donald E Moss
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 2.  Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.

Authors:  Seung Hyun Kim; Nagaendran Kandiah; Jung-Lung Hsu; Chuthamanee Suthisisang; Chesda Udommongkol; Amitabh Dash
Journal:  Br J Pharmacol       Date:  2017-10-29       Impact factor: 8.739

3.  Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging.

Authors:  Jamila Ahdidan; Cyrus A Raji; Edgar A DeYoe; Jedidiah Mathis; Karsten Ø Noe; Jens Rimestad; Thomas K Kjeldsen; Jesper Mosegaard; James T Becker; Oscar Lopez
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.